PolyPeptide Group has announced the appointment of Dr Raymond De Vré as CEO. He will succeed Jane Salik who will retain her role on the Board of Directors after 15 years as CEO.
De Vré will join PolyPeptide Group as CEO elect on 1 April 2021 and will work alongside Salik during a transition period prior to taking up his role as CEO over the course of the summer.
De Vré joins from Dr. Reddy's Laboratories where he is a member of the management council and Global Head of Biologics. Over the past 8 years, he has helped grow the biologics business by expanding it internationally, increasing manufacturing capacity and building a product pipeline in oncology and immunology. Prior to this, he spent 15 years with McKinsey & Company, where he was a partner advising pharmaceutical, biotech and specialty chemical companies in Europe, the US and India on M&A, growth strategies and operational improvements.
Salik has been with PolyPeptide Group since its incorporation as an independent company in 1996 and has more than quadrupled peptide sales and profits since 2006, when she became CEO. She has been responsible for PolyPeptide Group’s expansion into additional geographies across facilities.
Commenting on the changes, PolyPeptide Group Chairman, Jeffrey Hobbs, said: “The Board is delighted to have appointed Dr Raymond De Vré to the PolyPeptide Group as our next CEO. With more than two decades of relevant experience in the industry, Dr Raymond De Vré is a respected leader in the life sciences community, bringing skills and expertise which will make significant contributions to our continued long-term growth.
“On behalf of the entire PolyPeptide Group, I would like to thank Jane for her role in PolyPeptide Group’s growth during her outstanding tenure with the company. Her insights and leadership have guided us through a period of significant growth and I'm pleased that we will continue to benefit from her expertise as a member of the Board of Directors.”
De Vré added: "I am proud to join a company and management team with such exceptional industry knowledge, strong customer focus, unique culture, and track record of success. I am looking forward to building on these many successes to keep growing the PolyPeptide Group business in the years to come, capturing opportunities driven by innovation in the pharmaceutical and biotech industry.”
